07-22-2010... NOVELOS THERAPEUTICS ANNOUNCES $1.5 MILLION REGISTERED
DIRECT OFFERING...
See News
section for details...
07-12-2010... NOVELOS THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 RESULTS
IN NOV-002 NEOADJUVANT BREAST CANCER TRIAL AT SYLVESTER
COMPREHENSIVE CANCER CENTER, AT THE UNIVERSITY OF MIAMI...
See News
section for details...
About Us
Click Here for Corporate Slide Presentation
Click Here for Corporate Overview
Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized
glutathione-based compounds for the treatment of cancer and hepatitis. Novelos is
seeking to build a pipeline through licensing or acquiring clinical stage compounds
or technologies for oncology indications. Our lead compound, NOV-002, has been
administered to approximately 1,000 cancer patients in clinical trials and is in
Phase 2 development for solid tumors in combination with chemotherapy. Novelos has
a partnership with Mundipharma, an independent associated company of Purdue Pharma,
to develop and commercialize NOV-002 in Europe and Asia (excluding China). Novelos'
second compound, NOV-205, which has been administered to approximately 200 hepatitis
patients in clinical trials, is in Phase 2 development for chronic hepatitis C
non-responders.
Product Pipeline
We own all intellectual property rights worldwide (excluding the Russian Territory)
related to both of our clinical-stage compounds, i.e., NOV-002 and NOV-205, and
other pre-clinical compounds based on oxidized glutathione. We have six issued
patents in the U.S. We also have two issued patents in Europe and one in
Japan. Overall, we have filed more than 30 patent applications worldwide.